Neogenomics Stock Alpha and Beta Analysis
| NEO Stock | USD 11.17 0.28 2.45% |
This module allows you to check different measures of market premium (i.e., alpha and beta) for all equities such as NeoGenomics. It also helps investors analyze the systematic and unsystematic risks associated with investing in NeoGenomics over a specified time horizon. Remember, high NeoGenomics' alpha is almost always a sign of good performance; however, a high beta will depend on investors' risk tolerance level and may signal increased volatility and potential future overvaluation. Key technical indicators related to NeoGenomics' market risk premium analysis include:
Beta 0.93 | Alpha 0.11 | Risk 2.56 | Sharpe Ratio 0.0703 | Expected Return 0.18 |
Alpha is a measure of relative performance on a risk-adjusted basis, while beta measures volatility against the benchmark. The goal is to know if an investor is being compensated for the volatility risk taken. The return on investment might be better than its reference but still not compensate for the assumption of the risk.
NeoGenomics | Build AI portfolio with NeoGenomics Stock |
NeoGenomics Market Premiums
Investors always prefer to have the highest possible return on investment, coupled with the lowest possible volatility. NeoGenomics market risk premium is the additional return an investor will receive from holding NeoGenomics long position in a well-diversified portfolio. The market premium is part of the Capital Asset Pricing Model (CAPM), which most analysts and investors use to calculate the acceptable rate of return on investment in NeoGenomics. At the center of the CAPM is the concept of risk and reward, which is usually communicated by investors using alpha and beta measures. Alpha and beta are two of the key measurements used to evaluate NeoGenomics' performance over market.| α | 0.11 | β | 0.93 |
NeoGenomics expected buy-and-hold returns
Although buy-and-hold investment strategy may not appeal to all investors, it may be used as a good measure of NeoGenomics' Buy-and-hold return. Our buy-and-hold chart shows how NeoGenomics performed over your current time horizon against a typical interest-earning bank account and a selected benchmark.NeoGenomics Market Price Analysis
Market price analysis indicators help investors to evaluate how NeoGenomics stock reacts to ongoing and evolving market conditions. The investors can use it to make informed decisions about market timing, and determine when trading NeoGenomics shares will generate the highest return on investment. By understating and applying NeoGenomics stock market price indicators, traders can identify NeoGenomics position entry and exit signals to maximize returns.
NeoGenomics Return and Market Media
The median price of NeoGenomics for the period between Sat, Nov 15, 2025 and Fri, Feb 13, 2026 is 12.06 with a coefficient of variation of 6.94. The daily time series for the period is distributed with a sample standard deviation of 0.82, arithmetic mean of 11.87, and mean deviation of 0.64. The Stock received a lot of media exposure during the period. Price Growth (%) |
| Timeline |
1 | Earnings Scheduled For November 14, 2025 | 11/14/2025 |
2 | Disposition of 8776 shares by Warren Stone of NeoGenomics subject to Rule 16b-3 | 12/01/2025 |
3 | Team Vitality Charts Path To Esports Supremacy After Dominant 2025 | 12/05/2025 |
4 | NEO Battery Korea Institute for Defense Industry Form Joint Task Force to Advance Battery Integration in Commercial Drones | 12/23/2025 |
5 | Insider Trading | 12/31/2025 |
6 | Will Jack Kennys Board Appointment Reframe NeoGenomics Path From Specialized Lab Player To Scaled Platform | 01/07/2026 |
7 | Assessing NeoGenomics Valuation After Board Change Bringing In Diagnostics Veteran Jack Kenny | 01/12/2026 |
8 | Disposition of 15145 shares by Alicia Olivo of NeoGenomics subject to Rule 16b-3 | 01/13/2026 |
9 | How NeoGenomics CFO Transition and DoubleDigit Revenue Guidance Has Changed Its Investment Story | 01/16/2026 |
10 | Disposition of 22128 shares by Warren Stone of NeoGenomics at 12.5037 subject to Rule 16b-3 | 01/21/2026 |
11 | Contrasting NeoGenomics and AstraZeneca | 01/23/2026 |
12 | Assessing NeoGenomics Valuation After New 2025 Guidance And CFO Transition | 01/26/2026 |
13 | NEO Battery Demonstrates Step-Change Performance in Drone Batteries with Over 50 percent Capacity Improvement Versus Commercial Batteries | 01/29/2026 |
14 | NEO Battery Appoints 4-Star General Chang-Jun Ko, Former South Korean Army Chief of Staff, to its Board of Directors | 02/10/2026 |
15 | Disposition of 8977 shares by Alicia Olivo of NeoGenomics at 10.05 subject to Rule 16b-3 | 02/11/2026 |
About NeoGenomics Beta and Alpha
For many years both, Alpha and Beta indicators are used by professional money managers as critical performance measurement tools across virtually all financial instruments including NeoGenomics or other stocks. Alpha measures the amount that position in NeoGenomics has returned in comparison to a selected market index or another relevant benchmark. In other words, Alpha is the excess return on an investment relative to the performance of your selected benchmark. Beta, on the other hand, measures the relative risk of your investment.
| 2023 | 2024 | 2025 | 2026 (projected) | Payables Turnover | 17.07 | 17.15 | 15.43 | 16.2 | Days Of Inventory On Hand | 25.41 | 26.35 | 23.72 | 17.74 |
NeoGenomics Upcoming Company Events
As portrayed in its financial statements, the presentation of NeoGenomics' financial position is often influenced by management's estimates, judgments, and sometimes even manipulations. In the best case, NeoGenomics' leadership is honest, while the outside auditors are strict and uncompromising. Whatever the case, investors should always follow all of NeoGenomics' public filing events to personally review all filings and be reasonable and skeptical to interpret all of the financial statements of NeoGenomics. Please utilize our Beneish M Score to check the likelihood of NeoGenomics' management manipulating its earnings.
| 22nd of February 2024 Upcoming Quarterly Report | View | |
| 13th of May 2024 Next Financial Report | View | |
| 31st of December 2023 Next Fiscal Quarter End | View | |
| 22nd of February 2024 Next Fiscal Year End | View | |
| 30th of September 2023 Last Quarter Report | View | |
| 31st of December 2022 Last Financial Announcement | View |
Build Portfolio with NeoGenomics
Your optimized portfolios are the building block of your wealth. We provide an intuitive interface to determine which securities in a portfolio should be removed or rebalanced to achieve better diversification, find the right mix of securities that minimizes portfolio risk for a given return, or maximize portfolio expected return for a given risk level.Build Diversified Portfolios
Align your risk with return expectations
Check out NeoGenomics Analysis, NeoGenomics Valuation, NeoGenomics Correlation, NeoGenomics Hype Analysis, NeoGenomics Volatility, NeoGenomics Price History and analyze NeoGenomics Performance. To learn how to invest in NeoGenomics Stock, please use our How to Invest in NeoGenomics guide.You can also try the Fundamental Analysis module to view fundamental data based on most recent published financial statements.
NeoGenomics technical stock analysis exercises models and trading practices based on price and volume transformations, such as the moving averages, relative strength index, regressions, price and return correlations, business cycles, stock market cycles, or different charting patterns.